UK's AstronauTx Gets Cash For Alzheimer's Programs
The Dementia Discovery Fund is backing the UCL spin-off's efforts to develop therapies that modulate astrocyte function.
You may also be interested in...
Private Company Edition: The Dementia Discovery Fund started in 2015 with plans to raise $200m to fund early-stage development of disease-modifying drugs, but recently closed its fundraising with $350m in commitments. Also, Kaleido's $101m Series C is among three recent $100m-plus rounds.
Novartis’s cancer drug has now been filed for multiple sclerosis in the US, armed with a priority review, and in Europe.